Meningitis News and Research

Latest Meningitis News and Research

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

Financial Times examines product development partnerships developing drugs for neglected diseases

The Financial Times examines the rise of product development partnerships (PDPs), which are "non-governmental organizations that generate their own funding and build partnerships with universities, businesses, government and patients in low-income countries to develop new drugs, vaccines, prevention techniques and diagnostics for diseases such as tuberculosis, HIV, malaria, cholera and meningitis."

22 Jul 2011

NPR: Vaccine cost-benefit analysis complicates guidelines

The group that advises the U.S. government on vaccination thinks some new vaccines may not be worth the cost. In 2009, the Advisory Committee on Immunization Practices, or ACIP, decided it's not cost effective to routinely vaccinate boys for human papillomavirus, though they do recommend the vaccine for girls.

22 Jul 2011

Researchers closer to developing meningitis B vaccine

"New research may bring scientists one step closer to developing a vaccine that protects against hundreds of strains of meningococcus B, the most common cause of bacterial meningitis," according to research published last week in Science Translational Medicine, HealthDay News reports.

18 Jul 2011

Novel combined technique for treating neoplastic meningitis, hydrocephalus

Approximately five to ten percent of patients with primary or metastatic cancer suffer from devastating neurological complications such as headaches, seizures, confusion, difficulty swallowing and visual disturbances. These deficits are caused by a life-threatening form of brain invasion from cancer called neoplastic meningitis.

15 Jul 2011

Final Atlantis space trip may open new era of research into infectious diseases

On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.

7 Jul 2011

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

A powerful new class of therapeutics, known as recombinant attenuated Salmonella vaccines (RASV), holds great potential in the fight against fatal diseases including hepatitis B, tuberculosis, cholera, typhoid fever, AIDS and pneumonia.

30 Jun 2011

Copenhagen chemist reveals mechanism behind deadly infections

Anthrax, septicemia and meningitis are some of the planet's most deadly infections. In part because doctors lack basic insights to prevent and cure diseases caused by so called Gram-positive bacteria. Now, a chemist from the University of Copenhagen has revealed the mechanism behind these deadly infections.

24 Jun 2011

MA launches national campaign to raise awareness on meningitis

This Father's Day is a special day for Angels Dads on Meningitis (ADOM). Angel dads from across the country came together in Denver, Colorado to launch a national campaign on meningitis awareness.

20 Jun 2011

PEG hydrogel sealant effectively encloses surgical wounds after spinal procedures

A gel that creates a watertight seal to close surgical wounds provides a significant advance in the treatment of patients following spinal procedures, effectively sealing spinal wounds 100 percent of the time, a national multicenter randomized study led by researchers at UC Davis has found.

17 Jun 2011

Menafrivac more effective, less expensive than older meningitis vaccines, studies say

The meningococcal vaccine MenAfriVac, which is made by the Indian generic drug company Serum Institute, is "dramatically better" at producing a protective effect among African children in three countries than "older so-called meningococcal polysaccaride vaccines, including Mencevax from GlaxoSmithKline," according to a paper describing two studies published in the New England Journal of Medicine, Reuters reports.

17 Jun 2011

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France.

15 Jun 2011

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

New data from a pivotal study in more than 1,800 infants show that Novartis candidate vaccine Bexsero induces a robust immune response to meningococcal serogroup B when given alone or when co-administered with other routine vaccines.

15 Jun 2011

Meningitis vaccine showing success in West Africa

The New York Times reports on the success of a new meningococcal vaccine in West Africa, where very few cases of the disease have been detected in countries that use MenAfriVac, which costs 50 cents per dose.

15 Jun 2011

Low-cost meningitis vaccine cuts cases in African countries, data show

Burkina Faso, Mali and Niger recorded the lowest number of meningitis A cases in an epidemic season this year after the MenAfriVac vaccine was introduced, data from the WHO show, the nonprofit that helped develop the shot, Meningitis Vaccine Project (MVP), said on Thursday, Reuters reports.

13 Jun 2011

New opportunities to save another 6.4 million lives

Vaccinating children around the world against infectious diseases has saved the lives of millions over the past several decades. Now new opportunities exist to overcome remaining challenges-and save another 6.4 million lives over the current decade, according articles in the June 2011 edition of Health Affairs. The issue was produced under the journal's grant from the Bill & Melinda Gates Foundation.

10 Jun 2011

The ‘decade of vaccines’ has the potential to save lives, many challenges ahead

Vaccinating children around the world against infectious diseases has saved the lives of millions over the past several decades. Now new opportunities exist to overcome remaining challenges—and save another 6.4 million lives over the current decade, according articles in the June 2011 edition of Health Affairs. The issue was produced under the journal’s grant from the Bill & Melinda Gates Foundation.

9 Jun 2011

New vaccine leads to dramatic fall in meningitis A cases

Burkina Faso, Mali, and Niger report the lowest number of confirmed meningitis A cases ever recorded during an epidemic season this year following the successful introduction of a new vaccine that could eliminate the primary cause of the deadly disease from Africa's meningitis belt, announced the Meningitis Vaccine Project (MVP) today, which spearheaded development of the vaccine.

9 Jun 2011

Medical management preferred over surgery for pediatric orbital cellulitis

Researchers from Hasbro Children's Hospital in Providence, R.I., report that medical management may be preferred over surgery for children with orbital cellulitis, an acute infection of the tissues surrounding the eye. They have determined the criteria for surgical intervention should be dependent upon the size of a subperiosteal abscess (SPA).

9 Jun 2011

Meningitis News and Research

Latest Meningitis News and Research

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Financial Times examines product development partnerships developing drugs for neglected diseases

NPR: Vaccine cost-benefit analysis complicates guidelines

Researchers closer to developing meningitis B vaccine

Novel combined technique for treating neoplastic meningitis, hydrocephalus

Final Atlantis space trip may open new era of research into infectious diseases

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

Copenhagen chemist reveals mechanism behind deadly infections

MA launches national campaign to raise awareness on meningitis

PEG hydrogel sealant effectively encloses surgical wounds after spinal procedures

Menafrivac more effective, less expensive than older meningitis vaccines, studies say

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

Meningitis vaccine showing success in West Africa

Low-cost meningitis vaccine cuts cases in African countries, data show

New opportunities to save another 6.4 million lives

The ‘decade of vaccines’ has the potential to save lives, many challenges ahead

New vaccine leads to dramatic fall in meningitis A cases

Medical management preferred over surgery for pediatric orbital cellulitis

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Meningitis News and Research

Latest Meningitis News and Research

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in